Skip to main content
Erschienen in: Indian Journal of Surgical Oncology 3/2019

03.01.2019 | Original Article

Evaluation of Computed Tomography Scan and CA 125 Response in Predicting Operability in Advanced Ovarian Cancer and Assessing Survival Outcome in Interval Cytoreductive Surgery

verfasst von: P. Rema, Elizabeth Reshmi John, Suchetha Samabasivan, Anil Prahladan, Preethi George, J. Siva Ranjith, Shaji Thomas

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

The study aims at the prediction of optimal cytoreduction (OCR) in patients undergoing interval cytoreduction (ICR) in advanced epithelial ovarian cancer (AEOC) based on CT imaging and CA 125 values and assessing the survival pattern of these patients after ICR. This is a prospective observational study of patients with stage III C ovarian cancer who underwent ICR in our institution after neoadjuvant chemotherapy (NACT). All consecutive patients operated from April 2016 to October 2017 were included in the study. From their medical records, their demographic details and clinical variables were recorded. The CA 125 value and CT scan findings before and after chemotherapy were documented. A Bristow’s predictive score (BS) was calculated based on the radiological parameters. After ICR, the outcome of the surgery was documented. Optimal cytoreduction (OCR) was defined as no gross residual disease after surgery. The surgical outcome was correlated with the CA 125 difference pre and post chemotherapy and Bristow’s predictive score pre and post chemotherapy. The patients were followed up and their survival at 6 and 12 months was assessed. Univariate and multivariate analysis was done to identify factors predicting OCR. 51 patients were included in the study. Age group of the women ranged from 31 to 74 years with a mean of 52 years. Majority of the patients (70.6%) were postmenopausal. Of the 51 women, OCR could be achieved in 31 patients (60.8%). Post-chemotherapy, 36 patients had elevated CA125 above baseline of which 50% attained OCR. Forty six patients had CA 125 response post chemotherapy of which 67.4% attained OCR. Forty five patients had reduction in Bristow Score compared to the pre chemo values of which 64.4% attained OCR which was not found to be statistically significant. Overall survival was 100% survival at 6 months and 92.8% at 12 months in those who achieved OCR. Those with residual disease 0.1–1 cm had survival of 74.1% at 6 and 12 months. Those with residual disease > 1 cm had a survival of 50% at 6 and 12 months. CA125 response has a significant role in predicting OCR while CT evaluation using the BS was not useful in predicting OCR during ICR for AEOC.
Literatur
1.
Zurück zum Zitat Aletti GD, Gostout BS, Podratz KC et al (2006) Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. GynecolOncol 100:33–37 Aletti GD, Gostout BS, Podratz KC et al (2006) Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. GynecolOncol 100:33–37
2.
Zurück zum Zitat Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL et al (2000) A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89:1532–1540PubMedCrossRef Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL et al (2000) A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89:1532–1540PubMedCrossRef
3.
Zurück zum Zitat Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953PubMedCrossRef Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953PubMedCrossRef
4.
Zurück zum Zitat Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T et al (2015) Primarychemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open label, randomised, controlled, non-inferiority trial. Lancet Oncol 386(9990):249–257CrossRef Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T et al (2015) Primarychemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open label, randomised, controlled, non-inferiority trial. Lancet Oncol 386(9990):249–257CrossRef
5.
Zurück zum Zitat Stuart GCE, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J et al (2011) Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21:750Y755 Stuart GCE, Kitchener H, Bacon M, duBois A, Friedlander M, Ledermann J et al (2011) Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 21:750Y755
6.
Zurück zum Zitat Chi DS, Venkatraman ES, Masson V, Hoskins WJ (2000) The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77:227–231PubMedCrossRef Chi DS, Venkatraman ES, Masson V, Hoskins WJ (2000) The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77:227–231PubMedCrossRef
7.
Zurück zum Zitat Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC (2008) Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.15. Int J Gynecol Cancer 18(4):621–628PubMedCrossRef Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC (2008) Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.15. Int J Gynecol Cancer 18(4):621–628PubMedCrossRef
8.
Zurück zum Zitat Obeidat B, Latimer J, Crawford R (2004) Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Investig 57(3):153–156CrossRef Obeidat B, Latimer J, Crawford R (2004) Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Investig 57(3):153–156CrossRef
9.
10.
Zurück zum Zitat Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, Bergman A, Hricak H (2002) Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223:495–499PubMedCrossRef Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, Bergman A, Hricak H (2002) Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223:495–499PubMedCrossRef
11.
Zurück zum Zitat Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B (2005) Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 96(2):301–306PubMedCrossRef Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B (2005) Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 96(2):301–306PubMedCrossRef
12.
Zurück zum Zitat Nelson BE, Rosenfield AT, Schwartz PE (1993) Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 11:166–172PubMedCrossRef Nelson BE, Rosenfield AT, Schwartz PE (1993) Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 11:166–172PubMedCrossRef
13.
Zurück zum Zitat Forstner R, Hricak H, Occhipinti KA, Powell CB, Frankel SD, Stern JL (1995) Ovarian cancer: staging with CT and MR imaging. Radiology 197:619–626PubMedCrossRef Forstner R, Hricak H, Occhipinti KA, Powell CB, Frankel SD, Stern JL (1995) Ovarian cancer: staging with CT and MR imaging. Radiology 197:619–626PubMedCrossRef
14.
Zurück zum Zitat Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC (1995) Ovarian carcinoma: value of CT in predicting success of debulking surgery. Am J Roentgenol 165:875–878CrossRef Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC (1995) Ovarian carcinoma: value of CT in predicting success of debulking surgery. Am J Roentgenol 165:875–878CrossRef
15.
Zurück zum Zitat Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259PubMedCrossRef Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259PubMedCrossRef
17.
Zurück zum Zitat Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I et al (2012) Tenyear relative survival for epithelial ovarian cancer. Obstet Gynecol 120(3):612–618PubMedCrossRef Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I et al (2012) Tenyear relative survival for epithelial ovarian cancer. Obstet Gynecol 120(3):612–618PubMedCrossRef
Metadaten
Titel
Evaluation of Computed Tomography Scan and CA 125 Response in Predicting Operability in Advanced Ovarian Cancer and Assessing Survival Outcome in Interval Cytoreductive Surgery
verfasst von
P. Rema
Elizabeth Reshmi John
Suchetha Samabasivan
Anil Prahladan
Preethi George
J. Siva Ranjith
Shaji Thomas
Publikationsdatum
03.01.2019
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 3/2019
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-018-0868-x

Weitere Artikel der Ausgabe 3/2019

Indian Journal of Surgical Oncology 3/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.